Pharmaceutical and healthcare stocks that major mutual fund companies bet on in March

Net inflows have been higher over the past four months at lower market levels. Over the past few years, each sharp market decline has led to increased inflows indicating the maturity of retail investors, brokerage ICICI Securities pointed out in a note on mutual fund (MF) activity for the month. previous.

Inflows (formerly new fund offerings or NFOs) to equity UCITS continued to grow and reached a record level at 20,300 crores in March 2022 compared to 17,800 crore in Feb 2022. Systematic Investment Plan (SIP) inflows continued to rise and were strong at 12,300 crore in March.

According to the brokerage’s report, Biocon, Laurus Labs, Max Healthcare, Granules India, Apollo Hospitals were among the top healthcare and pharmaceutical stocks bought by mutual funds in the month of March.

Meanwhile, major fund companies like SBI MF, ICICI Prudential AMC bought more Apollo, Biocon and Zydus Lifesciences hospitals in the previous month, while Axis MF bet on Cipla and Fortis Healthcare and Mirae AMC took increased its stake in Laurus Labs, Gland Pharma and DSP MF in Max Santé.

All equity-based plans received net inflows in March 2022, with the multi-cap fund category being the main beneficiary with net inflows of 9,695 crore, followed by large and mid cap funds and large cap funds.

Overall, the mutual fund industry experienced a net outflow of 69,883 crore in March, compared to a net infusion of 31,533 crores in the previous month. Capital outflows caused the industry’s average assets under management (AUM) to fall to 37.7 lakh crore end of March, from 38 lakh crore at the end of February.

Catch all the trade news, market news, breaking news and latest updates on Live Mint. Download the Mint News app to get daily market updates.

More less

To subscribe to Mint Bulletins

* Enter a valid email

* Thank you for subscribing to our newsletter.

Dolores W. Simon